SARS-CoV-2 Variant Under Investigation 202012/01 has more than twofold replicative advantage

Frederic Grabowski; Grzegorz Preibisch; Marek Kochańczyk; Tomasz Lipniacki

doi:10.1101/2020.12.28.20248906

Abstract

The novel SARS-CoV-2 Variant Under Investigation VUI-202012/01 (also known as B.1.1.7), first collected on September 20, 2020, in Kent, is a rapidly growing lineage that in the first half of December 2020 constitutes more than 1/3 of all SARS-CoV-2 genomes sequenced in England. Based on GISAID data we have shown nearly exponential growth of the VUI-202012/01 to non-VUI-202012/01 genomes ratio in the five-week period since October 19 till November 22, 2020, with weekly growth rate of 2.31 [95% CI: 2.08–2.57]. Assuming the serial interval of 6.73 days we estimated the replicative advantage of VUI-202012/01 lineage as 2.31^6.73/7 = 2.24 [95% CI: 2.03–2.48]. Such significant replicative advantage and the fact that London serves as major international transportation hub suggest that the VUI-202012/01 strain will likely become globally dominant, hindering containment of the COVID-19 epidemics prior to massive vaccinations.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the National Science Centre (Poland) grant 2018/29/B/NZ2/00668.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This theoretical study is based on data published by GISAID and GOV.UK

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data used in this study are referenced. GISAID: www.gisaid.org; UK.GOV: https://coronavirus.data.gov.uk/details/cases

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.